Diagnosis and treatment of neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Lewy body dementia have historically been focused on identifying and treating symptoms. Symptoms can confound diagnosis, as many of these conditions have symptoms in common. Millions of people have had to forego an accurate diagnosis, instead propelled into a “diagnostic odyssey”—a journey in search of answers that are often not revealed until autopsy. Physicians have been limited in their ability to help patients access effective care for their disease, instead having to do their “best” with limited diagnostic tools. And most of today’s medicines aren’t curative, but simply help manage symptoms. 

It’s unlikely that any cure can be discovered without an understanding of each patient’s biology and how that is underlying the pathologies they experience. Through highly sensitive, early detection of misfolded proteins, Amprion is reimagining medicine for progressive neurodegeneration in a variety of CNS diseases. Amprion’s mission is to facilitate the end of Alzheimer’s, Parkinson’s, and other neurodegenerative disorders through early diagnostic testing, which provides the biological insights that inform discovery and give rise to effective treatments.